Skip to content

A multicenter, randomized, controlled clinical trial comparing the efficacy of Banxiaxiexin Decoction with Traditional Chinese Herbal Medicine in the Treatment of Chronic Non-Atrophic Gastritis

Chinese medicine formula particles national standard upgrade and comparison of efficacy of clinical decoction

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800014261
Enrollment
Unknown
Registered
2018-01-02
Start date
2018-01-02
Completion date
Unknown
Last updated
2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cold and heat cuza chronic non-atrophic gastritis

Interventions

treatment group:Banxia Xiexin decotion particles (Shineway brand)
control group:Banxia Xiexin decotion (traditional Chinese medicine)

Sponsors

Shijiazhuang Hospital of TCM
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) In line with western diagnostic criteria of chronic non-atrophic gastritis; (2) In line with traditional Chinese medicine syndrome - cold and heat mixed type dialectical standards; (3) Aged 18 ~ 80 years old male and female; (4) Voluntarily as a test subject, signed Informed Consent Forms.

Exclusion criteria

Exclusion criteria: (1) Combined with peptic ulcer, severe dysplasia of gastric mucosa or pathological diagnosis of suspected malignant transformation; (2) Patients with abnormal liver and kidney function (ALT, AST> 1.5 times upper limit of normal, Cr> 133µmol / L BUN> 7.5mmol/L); (3) Combined with heart, brain and hematopoietic system and other serious primary diseases; (4) 1 week application of aspirin, clopidogrel and blood coagulation drugs such as those who affect blood circulation; (5) Psychopath; (6) Pregnant or lactating women have a recent birth plan; (7) Allergies or allergies to many drugs.

Design outcomes

Primary

MeasureTime frame
before and after treatment Clinical symptoms (TCM symptom score) improvement rate;

Secondary

MeasureTime frame
Endoscopic gastric mucosal improvement rate before and after treatment;The rate of gastric mucosal pathological improvement before and after treatment;Patients before and after treatment to improve the quality of life points;

Countries

China

Contacts

Public ContactJinli Liu

Shijiazhuang Hospital of Traditional Chinese Medicine

670344215@qq.com+86 15133196552

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026